Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, April 7, 2015, 43 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $107.54 to $3,085,320.00.

Highlighted Stocks Traded by Insiders:

Destination XL Group (DXLG) - FREE Research Report

Ederle Kenneth, who is SVP,Chief MerchandisingOfficer at Destination XL Group, sold 60 shares at $3.82 on April 7, 2015. Following this transaction, the SVP,Chief MerchandisingOfficer owned 127,861 shares meaning that the stake was reduced by 0.05% with the 60-share transaction.

The shares most recently traded at $5.07, up $1.25, or 24.65% since the insider transaction. Historical insider transactions for Destination XL Group go as follows:

  • 4-Week # shares sold: 10,000
  • 12-Week # shares sold: 10,000
  • 24-Week # shares sold: 10,000

The average volume for Destination XL Group has been 75,300 shares per day over the past 30 days. Destination XL Group has a market cap of $254.5 million and is part of the services sector and retail industry. Shares are down 8.06% year-to-date as of the close of trading on Tuesday.

Destination XL Group, Inc., together with its subsidiaries, operates as a specialty retailer of big and tall men's apparel in the United States and England. Currently, there are 4 analysts who rate Destination XL Group a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DXLG - FREE

TheStreet Quant Ratings rates Destination XL Group as a sell. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself. Get the full Destination XL Group Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Ebix (EBIX) - FREE Research Report

Rennes Fondation, who is 10% Owner at Ebix, bought 15,000 shares at $29.43 on April 7, 2015. Following this transaction, the 10% Owner owned 3.7 million shares meaning that the stake was boosted by 0.41% with the 15,000-share transaction.

The shares most recently traded at $29.34, down $0.09, or 0.32% since the insider transaction. Historical insider transactions for Ebix go as follows:

  • 4-Week # shares bought: 20,000
  • 4-Week # shares sold: 58,445
  • 12-Week # shares bought: 20,000
  • 12-Week # shares sold: 58,445
  • 24-Week # shares bought: 20,000
  • 24-Week # shares sold: 58,445

The average volume for Ebix has been 487,200 shares per day over the past 30 days. Ebix has a market cap of $1.0 billion and is part of the technology sector and computer software & services industry. Shares are up 70.39% year-to-date as of the close of trading on Tuesday.

Ebix, Inc. provides software and e-commerce solutions to the insurance industry. The stock currently has a dividend yield of 1.04%. The company has a P/E ratio of 17.3. Currently, there is 1 analyst who rates Ebix a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EBIX - FREE

TheStreet Quant Ratings rates Ebix as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and attractive valuation levels. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Ebix Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Staar Surgical (STAA) - FREE Research Report

Gesten Samuel J, who is VP, General Counsel at Staar Surgical, sold 3,223 shares at $7.14 on April 7, 2015. Following this transaction, the VP, General Counsel owned 22,485 shares meaning that the stake was reduced by 12.54% with the 3,223-share transaction.

The shares most recently traded at $7.26, up $0.12, or 1.64% since the insider transaction. Historical insider transactions for Staar Surgical go as follows:

  • 4-Week # shares bought: 189,646
  • 4-Week # shares sold: 2,800
  • 12-Week # shares bought: 189,646
  • 12-Week # shares sold: 2,800
  • 24-Week # shares bought: 530,487
  • 24-Week # shares sold: 2,800

The average volume for Staar Surgical has been 344,400 shares per day over the past 30 days. Staar Surgical has a market cap of $282.8 million and is part of the health care sector and health services industry. Shares are down 19.32% year-to-date as of the close of trading on Tuesday.

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells implantable lenses for the eye, and delivery systems to deliver lenses into the eye. Currently, there is 1 analyst who rates Staar Surgical a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on STAA - FREE

TheStreet Quant Ratings rates Staar Surgical as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Staar Surgical Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null